Impact Newswire
Home / Global / FDA Approves Breakthrough Gene Therapies for Sickle Cell Disease

FDA Approves Breakthrough Gene Therapies for Sickle Cell Disease

The U.S. Food and Drug Administration (FDA) has recently given its approval for two groundbreaking treatments, Lyfgenia and Casgevy, offering new hope to patients with sickle cell disease.

Lyfgenia and Casgevy represent a significant leap in treating sickle cell disease, a hereditary blood disorder affecting around 100,000 Americans. Lyfgenia, developed by Bluebird Bio, employs gene-editing techniques to eliminate pain crises associated with the condition. Casgevy, a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR technology to turn on fetal hemoglobin, allowing red blood cells to maintain a healthy shape and alleviate pain crises in most patients. 

The FDA has encouraged post-approval studies by both Bluebird Bio and Vertex Pharmaceuticals to monitor patients for 15 years, emphasizing the importance of understanding the therapies’ long-term impact and potential side effects.

Source : https://www.researchandmarkets.com/issues/fda-approves-breakthrough-gene-therapies-for

The countdown is on for Digital Finance Africa (DFA) 2025, happening on Thursday, 3rd July 2025 at the prestigious Maslow Hotel in Sandton.
THE WORLD’S BIGGEST GATHERING OF YOUTH IN THE ENERGY GROUP
AI Film & Ad Fest Dubai

Discover more from Impact Newswire

Subscribe now to keep reading and get access to the full archive.

Continue reading